Cytokine Response to Abatacept in RA

Which cytokines (e.g., TNF-α, IL-2, IFN-γ) change most with abatacept treatment in RA?

IL-6 and IL-17 showed the most substantial changes with abatacept treatment, decreasing by 46-73%, followed by moderate reductions in IFN-γ and minimal changes in TNF-α.

Abstract

Ten studies evaluated cytokine changes following abatacept treatment in RA patients, employing before-after or cohort designs with treatment durations ranging from 16 weeks to over 5 years. Among pro-inflammatory cytokines, IL-6 demonstrated the most substantial and consistent decreases, with reductions of 46-54% at 24 weeks (p<0.001). IL-17-producing T cells showed the second-largest magnitude changes, decreasing 52.6-73% in clinical responders at 6-12 months (p≤0.017), with levels normalizing to those of healthy controls. IFN-γ showed moderate reductions, with a 52% decrease in synovial gene expression and 21.4% decrease in cellular production. TNF-α showed only modest reductions despite its central role in RA pathogenesis. Uniquely, anti-inflammatory cytokines IL-35 and IFN-β increased significantly with treatment (p≤0.0013).

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question. More on methods

Records from Elicit search

n = 200

Papers screened using: RA Population, Abatacept Intervention, Cytokine Measurements, Human Study, Adult Population, Study Design, RA-Specific Data, Publication Status

n = 200

Papers screened out

n = 190

Papers included for extraction

n = 10

Data extraction

We asked a large language model to extract data from each paper regarding study design, patient characteristics, abatacept treatment, cytokines measured, cytokine changes, measurement methods, and clinical correlations.

Results

Characteristics of included studies

All 10 included studies employed before-after or cohort designs to evaluate cytokine changes following abatacept treatment in RA patients.

Cytokines measured across studies

Studies employed varied methodological approaches to cytokine assessment. Cytokines measured included:

• IL-6: Pro-inflammatory; measured in plasma/serum.
• IL-17: Th17; measured in plasma/serum and cellular production.
• IFN-γ: Th1; measured in plasma/serum, cellular production, gene expression.
• TNF-α: Pro-inflammatory; measured in serum and gene expression.
• IL-35: Anti-inflammatory; measured in serum.

Effects of abatacept on cytokine levels

1. IL-6: Consistent and substantial reductions.
   • Baseline IL-6 levels decreased significantly after treatment (e.g., 24.9±20.5 pg/mL to 11.5±7.7 pg/mL; p<0.001).
2. IL-17: Marked reductions mainly measured as cellular production, normalized to levels comparable with healthy controls.
3. IFN-γ: Moderate reductions, with significant correlations to clinical improvement.
4. TNF-α: Modest reductions; less effective compared to others.
5. Anti-inflammatory cytokines: Significant increases in IL-35 and IFN-β levels.

Summary table of cytokine changes

Discussion

Abatacept primarily affects IL-6 and IL-17 pathways while having limited effects on TNF-α. The increase in anti-inflammatory cytokines indicates potential regulatory mechanisms in RA management.